Biogen sees continued revenue growth and pipeline readouts, M&A not essential, CEO says
Biogen reported third‑quarter earnings, marking a third straight quarter of revenue growth driven by its marketed products.
The increase stemmed from higher sales of the Alzheimer’s therapy Leqembi, the spinal muscular atrophy drug Spinraza, and products acquired in the $5.6 billion Apellis purchase.
CEO Chris Viehbacher said the company can keep expanding without relying on additional acquisitions, though deals remain a possible supplement, and highlighted several late‑stage readouts expected over the next year.
He described the late‑stage pipeline as “icing on the cake,” indicating new product launches will sit atop a growing revenue base.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Biogen set up for growth even without M&A but CEO won’t rule it out”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that